Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 4/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723522 | 0.92 | APP (0.46) | APPHSD11B1AVPR1AMAPTLTB4R | |
| SCHEMBL9607280 | 0.85 | APP (0.49) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12723380 | 0.84 | AVPR1A (0.47) | APPHSD11B1AVPR1A | |
| SCHEMBL9606867 | 0.79 | MAPT (0.51) | APPHSD11B1MAPT | |
| SCHEMBL12723460 | 0.77 | APP (0.44) | APPKDM4EGAAALDH1A1MAPT | |
| SCHEMBL6976978 | 0.77 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DAVPR1A | |
| SCHEMBL9607281 | 0.76 | APP (0.46) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12723383 | 0.71 | MAPT (0.49) | APPHSD11B1MAPT | |
| SCHEMBL20455885 | 0.70 | APP (0.49) | APPHSD11B1KDM4EGAAALDH1A1 | |
| SCHEMBL7002284 | 0.70 | APP (0.55) | APPPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2023-02-21 | — | — | US | disclosed |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-06-30 | — | — | US | disclosed |
| EP-3485883-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OccuRx Pty Ltd (AU) | 2019-05-22 | — | — | EP | disclosed |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| EP-2947073-A2 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics Pty Ltd (AU) | 2015-11-25 | — | — | EP | disclosed |
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-09-24 | — | — | US | disclosed |
| US-9062076-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| WO-2012068612-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | APP 4222/4885HSD11B1 2665/4885PDE4A 970/4885 |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | APP 4222/4885HSD11B1 2665/4885PDE4A 970/4885 |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | APP 3849/4885HSD11B1 2223/4885PDE4A 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.